Harnessing post-translational modifications for a tuberculosis booster vaccine

FHS
June 19, 2024
4:26 pm

Tuberculosis is still one of the deadliest infectious diseases, causing over one million deaths each year worldwide.

STAT Virtual Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us

December 1, 2023

Psilera Welcomes Biopharma Executive Dr. Magali Haas to its Board of Directors | Psychedelic Invest

TAMPA – Psilera, a leading biotechnology company developing groundbreaking therapies for hard-to-treat neurological disorders, is pleased to announce the appointment of Magali Haas, M.D., Ph.D., to its

March 28, 2024

MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results – Biotech Investments

EQS-News: MorphoSys AG / Key word(s): Quarterly / Interim Statement MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results 15.11.2023 / 22:01

November 16, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.